---
figid: PMC9115561__fonc-12-891812-g002
figtitle: 'RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular
  Carcinoma: Dream or Reality?'
organisms:
- NA
pmcid: PMC9115561
filename: fonc-12-891812-g002.jpg
figlink: /pmc/articles/PMC9115561/figure/f2/
number: F2
caption: 'Therapeutic targets in HCC pathways: Angiogenesis: CXCR4/MDM2(chemokine
  receptor/murine double minute 2 protein), CTLA-4 (constitutively expressed in regulatory
  T cells), HIF-1α (hypoxia-inducible factor 1-alpha, a subunit of a heterodimeric
  transcription factor hypoxia-inducible factor 1 that is encoded by the HIF1A gene),
  VEGF (vascular endothelial growth factor, stimulates the formation of blood vessels),
  Cell proliferation: TERT (telomerase reverse transcriptase, a catalytic subunit
  of telomerase, EGFR (epidermal growth factor receptor), CDCA1 (Cell division cycle
  associated 1, an oncoantigen), MYC (transcription factor, proto-oncogene), MCL-1
  (induced myeloid leukaemia cell differentiation protein), ARL4C (ADP-ribosylation
  factor-like 4C). Apoptosis: BIRC5/Survivin (baculoviral inhibitor of apoptosis repeat-containing
  5 or survivin), BCL-2 (B-cell lymphoma 2, regulatory protein inducing or inhibiting
  apoptosis), hBAX (human Bcl-2-associated X protein, apoptosis regulator), HDCA2
  (histone deacetylase 2, removed acetyl groups from lysine at the N’ terminal of
  core histones). Receptors: VEGFR (vascular endothelial growth factor receptor),
  IGFR (insulin-like growth factor receptor), EGFR (epithelial growth factor receptor),
  FGFR (fibroblast growth factor receptor), PDGFR (platelet-derived growth factor
  receptor), C-MET (tyrosine-protein kinase Met or hepatocyte growth factor receptor
  (HGFR)), WNT (Wingless and Int-1). Pathways: JAK/STAT (Janus kinase (JAK)-signal
  transducer and activator of transcription (STAT)), P13/AKT/mTOR (phosphatidylinositol-3-kinase
  (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signalling pathway), RTKs
  (receptor tyrosine kinases), RAS/RAF/MEK/ERK (extracellular signal-regulated kinases),
  WNT/B-CATENIN (highly conserved pathway).'
papertitle: 'RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular
  Carcinoma: Dream or Reality?.'
reftext: Kurt Sartorius, et al. Front Oncol. 2022;12:891812.
year: '2022'
doi: 10.3389/fonc.2022.891812
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: small interfering RNA (siRNA) | antisense oligonucleotide (ASO) | aptamer
  | ribozyme | riboswitch | CRISPR/Cas9 | RNAi strategies
automl_pathway: 0.9585397
figid_alias: PMC9115561__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC9115561__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9115561__fonc-12-891812-g002.html
  '@type': Dataset
  description: 'Therapeutic targets in HCC pathways: Angiogenesis: CXCR4/MDM2(chemokine
    receptor/murine double minute 2 protein), CTLA-4 (constitutively expressed in
    regulatory T cells), HIF-1α (hypoxia-inducible factor 1-alpha, a subunit of a
    heterodimeric transcription factor hypoxia-inducible factor 1 that is encoded
    by the HIF1A gene), VEGF (vascular endothelial growth factor, stimulates the formation
    of blood vessels), Cell proliferation: TERT (telomerase reverse transcriptase,
    a catalytic subunit of telomerase, EGFR (epidermal growth factor receptor), CDCA1
    (Cell division cycle associated 1, an oncoantigen), MYC (transcription factor,
    proto-oncogene), MCL-1 (induced myeloid leukaemia cell differentiation protein),
    ARL4C (ADP-ribosylation factor-like 4C). Apoptosis: BIRC5/Survivin (baculoviral
    inhibitor of apoptosis repeat-containing 5 or survivin), BCL-2 (B-cell lymphoma
    2, regulatory protein inducing or inhibiting apoptosis), hBAX (human Bcl-2-associated
    X protein, apoptosis regulator), HDCA2 (histone deacetylase 2, removed acetyl
    groups from lysine at the N’ terminal of core histones). Receptors: VEGFR (vascular
    endothelial growth factor receptor), IGFR (insulin-like growth factor receptor),
    EGFR (epithelial growth factor receptor), FGFR (fibroblast growth factor receptor),
    PDGFR (platelet-derived growth factor receptor), C-MET (tyrosine-protein kinase
    Met or hepatocyte growth factor receptor (HGFR)), WNT (Wingless and Int-1). Pathways:
    JAK/STAT (Janus kinase (JAK)-signal transducer and activator of transcription
    (STAT)), P13/AKT/mTOR (phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian
    target of rapamycin (mTOR) signalling pathway), RTKs (receptor tyrosine kinases),
    RAS/RAF/MEK/ERK (extracellular signal-regulated kinases), WNT/B-CATENIN (highly
    conserved pathway).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MDM2
  - CXCR4
  - HIF1A
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - CTLA4
  - CCL2
  - CCR2
  - TERT
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - EGFR
  - MTOR
  - EXOSC1
  - H3P6
  - AKT1
  - AKT2
  - AKT3
  - IGF1R
  - KDR
  - FLT1
  - FLT4
  - NUF2
  - MYC
  - MCL1
  - KRAS
  - HRAS
  - NRAS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EPHB2
  - MAPK1
  - MAPK3
  - ARL4C
  - BIRC5
  - PDGFRB
  - PDGFRA
  - MET
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - CTNNB1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - BCL2
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - TGFBR1
  - TGFBR2
  - TGFBR3
---
